Table 1.
Baseline Clinical and Biochemical Characteristics of Obese Type 2 Diabetes Patients Treated with Supplementary Insulin or Implanted with a Gastric Contractility Modulator
| GCM group (n=8) | INS group (n=8) | P value | |
|---|---|---|---|
| Male (%) | 5 (63%) | 6 (75%) | 1.000 |
| Age (years) | 43.9 (3.7) | 49.3 (2.6) | 0.382 |
| Body weight (kg) | 80.4 (4.0) | 86.0 (4.3) | 0.279 |
| Body mass index (kg/m2) | 29.4 (0.7) | 30.8 (1.6) | 0.202 |
| Waist circumference (cm) | 98.9 (0.8) | 104.5 (3.0) | 0.234 |
| Body fat (%) | 33.5 (2.4) | 28.6 (1.5) | 0.105 |
| Duration of diabetes (years) | 14.3 (2.0) | 11.0 (2.4) | 0.279 |
| Fasting C-peptide (μg/L) | 2.9 (0.5) | 2.9 (0.3) | 0.959 |
| HbA1c (%) | 9.1 (0.3) | 8.9 (0.3) | 0.798 |
| DM drug usage | |||
| Sulfonylureas | 7 (88%) | 5 (63%) | 0.569 |
| Metformin | 8 (100%) | 8 (100%) | 1.000 |
| Thiazolidinedione | 0 (0%) | 2 (25%) | 0.467 |
| α-Glucosidase inhibitors | 2 (25%) | 3 (37.5%) | 1.000 |
| DPP-4 inhibitors | 0 (0%) | 1 (13%) | 1.000 |
| DM complications | |||
| Retinopathy | 1 (13%) | 2 (25%) | 0.467 |
| Neuropathy | 0 (0%) | 0 (0%) | 1.000 |
| Cardiovascular | 1 (13%) | 0 (0%) | 1.000 |
| Nephropathy | 0 (0%) | 0 (0%) | 1.000 |
Data are mean (SEM) values or number (%), as indicated.
DM, diabetes mellitus; DPP-4, dipeptidyl peptidase-4; GCM, gastric contractility modulator; HbA1c, glycated hemoglobin; INS, insulin.